| Sipkoff M
Rebates for anti-anemia drugs draw response from FDA, CMS. [Journal Article]
Manag Care 2007 Jun; 16(6):17-8.
Full Citation | Find Related Articles |
| Steinbrook R
Erythropoietin, the FDA, and oncology. [Journal Article]
N Engl J Med 2007 Jun 14; 356(24):2448-51.
Full Citation | Publisher Full Text | Find Related Articles |
| Steensma DP
New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony. [Journal Article]
J Support Oncol 2007 Nov-Dec; 5(10):471-3.
Full Citation | Find Related Articles |
| Messana T
Erythropoietin claims monitoring policy: implications of the October 2006 update continuing. [Journal Article, Research Support, Non-U.S. Gov't]
Nephrol Nurs J 2006 Nov-Dec; 33(6):660-3; quiz 664-5.
Abstract | Full Citation | Find Related Articles |
| Epoetins and [symbol: see text] darbepoetin alfa in malignant disease. [Journal Article, Review]
Drug Ther Bull 2004 Mar; 42(3):21-3.
Abstract | Full Citation | Find Related Articles |
| Messana A
Finding a rational approach to ESA therapy--for payers and patients. [Journal Article]
Nephrol News Issues 2007 Sep; 21(10):54, 56.
Full Citation | Find Related Articles |
| Messana T
Erythropoietin claims monitoring policy: implications for clinical practice. [Journal Article, Review]
Nephrol Nurs J 2006 Mar-Apr; 33(2):209-13, 222; quiz 214-5.
Abstract | Full Citation | Find Related Articles |
| Reed SD, Radeva JI, Daniel DB, et al.
Economic Evaluation of Weekly Epoetin Alfa versus Biweekly Darbepoetin Alfa for Chemotherapy-Induced Anaemia : Evidence from a 16-Week Randomised Trial. [Journal Article]
Pharmacoeconomics 2006; 24(5):479-94.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Sullivan JD
Has economics overshadowed our clinical approaches to EPO? [Journal Article]
Nephrol News Issues 2007 Jul; 21(8):56, 58-9, 68.
Full Citation | Find Related Articles |
  |
